Advanced Enzyme Technologies Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Advanced Enzyme Technologies Ltd filed with BSE on 18 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Advanced Enzyme Technologies reported Q1 FY27 revenue of INR 1,898 million, up 2% YoY but down 7% sequentially, with management attributing the softness to an incremental sales reversal of INR 100 million related to revenue recognition timing. EBITDA declined 10% YoY to INR 510 million with margin at 27%, which management said was due to lower top-line realization, elevated power and fuel costs, and a temporary shift in sales mix. The company also announced a buyback of INR 697 million and the acquisition of the remaining 4.28% stake in JC Biotech, making it a wholly-owned subsidiary.
Numbers mentioned
Revenue: INR 1,898 million (Q1 FY27)
p. 3
“Our top line for the quarter stood at INR 1,898 million, registering a 2% YoY growth.”
Mukund Kabra, page 3 of the filed PDF · View the filing
EBITDA: INR 510 million (Q1 FY27)
p. 4
“EBITDA for the quarter came in at INR 510 million, down 10% YoY and 19% QoQ.”
Mukund Kabra, page 4 of the filed PDF · View the filing
EBITDA margin: 27% (Q1 FY27)
p. 4
“Consequently, the EBITDA margin stood at 27% compared to 30% in Q1 FY26 and 31% in Q4 FY26.”
Mukund Kabra, page 4 of the filed PDF · View the filing
Profit after tax: INR 386 million (Q1 FY27)
p. 4
“Moving to profitability, profit after tax stood at INR 386 million declining 5% YoY and 15% sequentially.”
Mukund Kabra, page 4 of the filed PDF · View the filing
PAT margin: 20% (Q1 FY27)
p. 4
“The PAT margin for the quarter was 20% compared to 22% in both Q1 FY26 and Q4 FY26.”
Mukund Kabra, page 4 of the filed PDF · View the filing
Human Healthcare revenue: INR 1,139 million (Q1 FY27)
p. 4
“Revenues from Q1 FY27 stood at INR 1,139 million, reflecting a 7% YoY decline and 11% sequential decline.”
Mukund Kabra, page 4 of the filed PDF · View the filing
Animal Healthcare revenue: INR 252 million (Q1 FY27)
p. 4
“Moving to Animal Healthcare: Revenue stood at INR 252 million, registering a 3% YoY decline while growing 1% QoQ.”
Mukund Kabra, page 4 of the filed PDF · View the filing
Bioprocessing revenue: INR 306 million (Q1 FY27)
p. 4
“Turning to Bioprocessing, the segment reported revenues of INR 306 million, delivering 30% YoY growth.”
Mukund Kabra, page 4 of the filed PDF · View the filing
Specialized Manufacturing revenue: INR 200 million (Q1 FY27)
p. 4
“Lastly, Specialized Manufacturing reported revenues of INR 200 million, registering a robust 41% YoY growth and 11% increase over the previous quarter.”
Mukund Kabra, page 4 of the filed PDF · View the filing
Buyback size: INR 697 million at ceiling price of INR 500 per share
p. 4
“We are pleased to announce that the Board has approved a buyback of INR 697 million at a ceiling price of INR 500 per share via open market route.”
Mukund Kabra, page 4 of the filed PDF · View the filing
JC Biotech stake acquisition: 4.28% for INR 79.79 million
p. 4
“The company has also announced the acquisition of the remaining stake of 4.28% for a consideration of INR 79.79 million in our existing subsidiary, JC Biotech, resulting in a total stake of 100%, making it wholly-owned subsidiary.”
Mukund Kabra, page 4 of the filed PDF · View the filing
R&D expenditure: INR 90 million (Q1 FY27)
p. 5
“R&D expenditure, we have spent about INR 90 million in the Q1 of FY27 as compared to INR 86 million in Q1 of FY26.”
Beni Prasad Rauka, page 5 of the filed PDF · View the filing
Inventory: INR 190 crores (as on 30th June 2026)
p. 19
“Inventory, 30th June 2026, was about INR 190 crores.”
Beni Prasad Rauka, page 19 of the filed PDF · View the filing
Working capital cycle: 125-138 days
p. 19
“In terms of number of days, generally our working capital cycle is about 125-138 days.”
Beni Prasad Rauka, page 19 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — double digits · FY27
stated conditionally by Mukund Kabra
p. 9
“As of now, we think we should be able to grow in double digits.”
Mukund Kabra, page 9 of the filed PDF · View the filing
EBITDA margin — 30-32%
stated firmly by Mukund Kabra
p. 17
“See, R&D always helps in increasing the margins. But as of now, we will just like to continue that we will be having a 30-32% of EBITDA margin, and that is what we are saying.”
Mukund Kabra, page 17 of the filed PDF · View the filing
U.S. business growth — 8-10%
stated as an aspiration by Beni Prasad Rauka
p. 8
“kind of the growth we can expect is, as we always say, U.S., we don't expect at least at this juncture beyond 8-10% of growth.”
Beni Prasad Rauka, page 8 of the filed PDF · View the filing
U.S. business growth — about 8% · by end of the year
stated conditionally by Beni Prasad Rauka
p. 13
“As we progress, we will get more clarity, and I think we expect that we shall be having a better growth in the coming quarters. I think by the end of the year, it should be about 8% or so.”
Beni Prasad Rauka, page 13 of the filed PDF · View the filing
CapEx — INR 123 crores · FY27
stated firmly by Beni Prasad Rauka
p. 6
“This is what we are going to spend.”
Beni Prasad Rauka, page 6 of the filed PDF · View the filing
Biocatalysis segment growth — second half of the year
stated as an aspiration by Mukund Kabra
p. 11
“It's still the high-growth segment for us. This year, we expect in the second half, good growth should come from this area.”
Mukund Kabra, page 11 of the filed PDF · View the filing
EBITDA margin recovery — about 30%
stated conditionally by Beni Prasad Rauka
p. 14
“Yes. We expect that it shall come back to the normal level of about 30% of EBITDA.”
Beni Prasad Rauka, page 14 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said around INR 20 crore is normal capex, INR 50 crore is for R&D already under work in progress, and the balance is for growth.
Answered by Beni Prasad Rauka
Asked by Abhishek Navalgund: How much of the INR 123 crore capex is growth capex versus maintenance capex?
p. 6
“Out of this, I think INR 20 crore is normal capital expenditure. INR 50 crores will go for R&D, which is already under work in progress.”
Beni Prasad Rauka, page 6 of the filed PDF · View the filing
Management said that including the incremental reversal, growth this quarter would be about 8%, and expressed confidence in achieving prior growth guidance as the year progresses.
Answered by Beni Prasad Rauka
Asked by Zaki Nasser: Can the company close the year with at least 12% growth given the sales reversal impact?
p. 9
“As we progress, we are confident that we shall be able to achieve the kind of growth numbers which we have shared with you in past.”
Beni Prasad Rauka, page 9 of the filed PDF · View the filing
Management confirmed realization improved due to price increases but declined to quantify it.
Answered by Beni Prasad Rauka
Asked by Umang Shah: Is pricing better this quarter compared to last year for the largest product?
p. 11
“Pricing is better in this particular quarter because we have increased some prices. It's better in that sense. Realization is better than Q4 and Q1 of last year.”
Beni Prasad Rauka, page 11 of the filed PDF · View the filing
Management attributed the flat performance to geopolitical issues and an ongoing shift to branding strategy, expecting improvement over time.
Answered by Beni Prasad Rauka
Asked by Shreyans Gathani: What is driving the decline/flatness in the U.S. business and what is being done to fix it?
p. 13
“I think we have explained you that we are expecting 8-10% of growth in our U.S. business.”
Beni Prasad Rauka, page 13 of the filed PDF · View the filing
Management said the EFSA approval process is ongoing and could take three to six months or longer, depending on regulatory queries.
Answered by Mukund Kabra
Asked by Ketan Chheda: Is there an update on the novel food application status?
p. 16
“Right now, we are waiting for EFSA approval. I guess, like, you asked for the novel food approval, right? We are waiting for that. Maybe three months to six months, we should wait.”
Mukund Kabra, page 16 of the filed PDF · View the filing
Management said one patent (Alternansucrase for sugar management) was granted in the U.S., another on protein was likely granted, and the third is still under process.
Answered by Mukund Kabra
Asked by Rohit Ohri: What is the status of the three patent applications for sugar management, gluten intolerance mitigation, and biocatalysis?
p. 17
“We need to check, but I guess we got one patent on Alternansucrase on the sugar management. We already granted U.S. patent.”
Mukund Kabra, page 17 of the filed PDF · View the filing
Management said they are not currently pursuing the DHA molecule but might revisit it once the new R&D facility is operational.
Answered by Mukund Kabra
Asked by Rohit Ohri: Is the Algae DHA project from JC Biotech being revived?
p. 18
“We are not going forward with the DHA as of now, which was JC Biotech’s molecule. As of now, we are not really working on that at current level.”
Mukund Kabra, page 18 of the filed PDF · View the filing
Management said not to focus on quarter-on-quarter comparisons, noting the sales reversal impact and a slow quarter for the pharma segment, while expressing confidence in staying on track.
Answered by Mukund Kabra
Asked by Nikhil Upadhyay: What explains the sharp deceleration in growth compared to the strong 20%+ growth in prior quarters?
p. 19
“Probably, we expect a strong momentum from the next quarter because sometimes, there are some inventory issues and some other issues, which all accounts at the customer level, at your levels, and all of those are the complicates.”
Mukund Kabra, page 19 of the filed PDF · View the filing
Risks flagged
Global geopolitical tensions and trade uncertainties disrupting operations
p. 3
“The global economy has been experiencing significant disturbance for quite some time, primarily driven by geographical tensions, trade and uncertainties, and continued disruption across global supply chain.”
Mukund Kabra, page 3 of the filed PDF · View the filing
Elevated power and fuel costs due to global energy disruption impacting margins
p. 4
“Our consolidated margins moderated primarily due to three factors: lower top-line realization, elevated power and fuel costs driven by global energy disruption, and a temporary shift in the sales mix.”
Mukund Kabra, page 4 of the filed PDF · View the filing
Unfavorable U.S. business environment affecting growth
p. 7
“I think overall, if you see the situation in the U.S., it's not so conducive as of now.”
Beni Prasad Rauka, page 7 of the filed PDF · View the filing
Geopolitical situation including tariff issues and the Iran war affecting the business
p. 8
“Even the tariff issue. Lakshmi Narayanan ji, all of a sudden, the tariff issue was there, then we affect those program, and then this Iran war that has created some kind of issues.”
Beni Prasad Rauka, page 8 of the filed PDF · View the filing
Hiring challenges in the market
p. 8
“In addition to that, what has happened in the market in last two years, even hiring people have become a big challenge in the process.”
Beni Prasad Rauka, page 8 of the filed PDF · View the filing
Incremental sales reversal from goods in transit not reaching customers
p. 3
“On account of revenue recognition accounting principles, this quarter was impacted by an additional sales reversal amounting to INR 100 million over and above reversal of revenue generally being accounted in every quarter.”
Mukund Kabra, page 3 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.